The historical data trend for DT&CRO Co's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, DT&CRO Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DT&CRO Co's EV-to-EBIT Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, DT&CRO Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where DT&CRO Co's EV-to-EBIT falls into.
DT&CRO Co EV-to-EBIT Calculation
DT&CRO Co's EV-to-EBIT for today is calculated as:
DT&CRO Co's current Enterprise Value is ₩119,066 Mil.
DT&CRO Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-20,667 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DT&CRO Co (XKRX:383930) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
DT&CRO Co's Enterprise Value for the quarter that ended in Mar. 2024 was ₩115,338 Mil.
DT&CRO Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-20,667 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DT&CRO Co EV-to-EBIT Related Terms
Thank you for viewing the detailed overview of DT&CRO Co's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
DT&CRO Co Ltd conducts a series of consigned research, from non-clinical GLP toxicity, PK, and efficacy tests required for licensing of pharmaceuticals, chemicals, health functional foods, cosmetics and medical devices, to analysis, bioactivity, clinical trials, and licensing consulting. provided as a service.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XKRX:383930 has been successfully added to your 